Results 21 to 30 of about 8,527,959 (316)
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Cancer Communications, 2018 Background 5-Fluorouracil (5-FU) and capecitabine-associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese ...
Jianjun Peng +15 more
doaj +1 more source
Assessment of Alpha-fetoprotein levels and the effect of 5- Fluorouracil on Cytotoxicity of HepG2 cell line [PDF]
Alfarama Journal of Basic & Applied Sciences, 2022 Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide nowadays. In Egypt, the cancer is frequently discovered at an advanced stage, at which no therapy, even surgery, is successful.
Nabil Abdel-Hamid +3 more
doaj +1 more source
Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance
Tumor Biology, 2017 5-Fluorouracil is a classic chemotherapeutic drug that is widely used to treat various cancers. However, patients often exhibit primary or acquired drug resistance during treatment with 5-fluorouracil chemotherapy.
Jun Deng +4 more
doaj +1 more source
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
Pharmaceutics, 2019 5-Fluorouracil remains a foundational component of chemotherapy for solid tumour malignancies. While considered a generally safe and effective chemotherapeutic, 5-fluorouracil has demonstrated severe adverse event rates of up to 30%.
Theodore J. Wigle +3 more
doaj +1 more source
Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? [PDF]
, 2010 Background 5-Fluorouracil remains widely used in colorectal cancer treatment more than 40 years after its development. 19F magnetic resonance spectroscopy can be used in vivo to measure 5FU’s half-life and metabolism to cytotoxic fluoronucleotides ...
Griffiths, John R. +17 more
core +1 more source
Corneal Epithelial Hyperplasia after 5-Fluorouracil Injection
Case Reports in Ophthalmology, 2018 Background: 5-Fluorouracil (5-FU) is a pyrimidine analogue which selectively inhibits DNA synthesis, RNA synthesis, and VEGF antibodies. 5-FU is widely used in ophthalmology for inhibition of postoperative corneal scarring and scleral bleb fibrosis. Case
Dania A. Bukhari +2 more
doaj +1 more source
Molecular Therapy: Oncolytics, 2023 TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modifications to ...
Jérémy Béguin +15 more
doaj +1 more source
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases [PDF]
, 2002 Background: The management of recurrent, metastatic cholangiocarcinoma still remains a problem since this tumor entity is classified as chemotherapy-resistant.
Schalhorn, A. +2 more
core +1 more source
5-Fluorouracil/Coumarin and 5-Fluorouracil/Chromone Hybrids: Synthesis and Drug-Likeness Modeling
MolbankA series of 5-fluorouracil/coumarin and 5-fluorouracil/chromone hybrids were synthesized with good yields using click chemistry as the key step.
Laura Giraldo-Arroyave +2 more
doaj +1 more source